FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2954234894> ?p ?o ?g. }

• W2954234894 endingPage "1172" @default.
• W2954234894 startingPage "1161" @default.
• W2954234894 abstract "The progression of kidney disease in some patients with type 2 diabetes mellitus may not be adequately suppressed by renin-angiotensin system inhibitors. Esaxerenone (CS-3150) is a nonsteroidal mineralocorticoid receptor blocker that has shown kidney protective effects in preclinical studies, and it is a potential add-on therapy to treat diabetic kidney disease. This phase 2 study evaluated the efficacy and safety of esaxerenone in Japanese patients with type 2 diabetes mellitus and microalbuminuria.This multicenter, randomized, double-blind, placebo-controlled trial enrolled 365 hypertensive or normotensive patients with type 2 diabetes mellitus and microalbuminuria (urinary albumin-to-creatinine ratio ≥45 to <300 mg/g creatinine) treated with renin-angiotensin system inhibitor who had eGFR≥30 ml/min per 1.73 m2. Participants were randomized to receive 0.625, 1.25, 2.5, or 5 mg/d esaxerenone or placebo for 12 weeks. The primary end point was the change in urinary albumin-to-creatinine ratio from baseline to week 12 (with last observation carried forward).Esaxerenone treatment at 1.25, 2.5, and 5 mg/d significantly reduced urinary albumin-to-creatinine ratio by the end of treatment (38%, 50%, and 56%, respectively) compared with placebo (7%; all P<0.001). The urinary albumin-to-creatinine ratio remission rate (defined as urinary albumin-to-creatinine ratio <30 mg/g creatinine at the end of treatment and ≥30% decrease from baseline) was 21% in the 2.5- and 5-mg/d groups versus 3% for placebo (both P<0.05). Adverse events occurred slightly more frequently with esaxerenone versus placebo, but the frequencies of drug-related adverse events and discontinuation rates were similar in the placebo and the 0.625-, 1.25-, and 2.5-mg/d groups. Drug-related adverse events and treatment discontinuations were marginally higher in the 5-mg/d group. The most common drug-related adverse event was hyperkalemia, which was dose proportional.Adding esaxerenone at 1.25, 2.5, and 5 mg/d for 12 weeks to an ongoing renin-angiotensin system inhibitor significantly reduces urinary albumin-to-creatinine ratio in patients with type 2 diabetes mellitus and microalbuminuria." @default.
• W2954234894 created "2019-07-12" @default.
• W2954234894 creator A5003990451 @default.
• W2954234894 creator A5036113498 @default.
• W2954234894 creator A5063387177 @default.
• W2954234894 creator A5066495888 @default.
• W2954234894 creator A5080291594 @default.
• W2954234894 date "2019-06-27" @default.
• W2954234894 modified "2023-10-18" @default.
• W2954234894 title "Efficacy and Safety of Esaxerenone (CS-3150) for the Treatment of Type 2 Diabetes with Microalbuminuria" @default.
• W2954234894 cites W1830102405 @default.
• W2954234894 cites W1884587593 @default.
• W2954234894 cites W1972358173 @default.
• W2954234894 cites W1983917438 @default.
• W2954234894 cites W2019270553 @default.
• W2954234894 cites W2020811647 @default.
• W2954234894 cites W2020920396 @default.
• W2954234894 cites W2072070798 @default.
• W2954234894 cites W2072124509 @default.
• W2954234894 cites W2086240954 @default.
• W2954234894 cites W2109069299 @default.
• W2954234894 cites W2129223025 @default.
• W2954234894 cites W2132715232 @default.
• W2954234894 cites W2152189242 @default.
• W2954234894 cites W2156825907 @default.
• W2954234894 cites W2168712739 @default.
• W2954234894 cites W2169855498 @default.
• W2954234894 cites W2173089390 @default.
• W2954234894 cites W2206859595 @default.
• W2954234894 cites W2466427330 @default.
• W2954234894 cites W2602037410 @default.
• W2954234894 cites W2620856578 @default.
• W2954234894 cites W2735652746 @default.
• W2954234894 cites W2794676804 @default.
• W2954234894 cites W2802617131 @default.
• W2954234894 cites W2908535040 @default.
• W2954234894 cites W2909182150 @default.
• W2954234894 cites W2917732217 @default.
• W2954234894 cites W4255926242 @default.
• W2954234894 doi "https://doi.org/10.2215/cjn.14751218" @default.
• W2954234894 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6682830" @default.
• W2954234894 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31248950" @default.
• W2954234894 hasPublicationYear "2019" @default.
• W2954234894 type Work @default.
• W2954234894 sameAs 2954234894 @default.
• W2954234894 citedByCount "76" @default.
• W2954234894 countsByYear W29542348942019 @default.
• W2954234894 countsByYear W29542348942020 @default.
• W2954234894 countsByYear W29542348942021 @default.
• W2954234894 countsByYear W29542348942022 @default.
• W2954234894 countsByYear W29542348942023 @default.
• W2954234894 crossrefType "journal-article" @default.
• W2954234894 hasAuthorship W2954234894A5003990451 @default.
• W2954234894 hasAuthorship W2954234894A5036113498 @default.
• W2954234894 hasAuthorship W2954234894A5063387177 @default.
• W2954234894 hasAuthorship W2954234894A5066495888 @default.
• W2954234894 hasAuthorship W2954234894A5080291594 @default.
• W2954234894 hasBestOaLocation W29542348941 @default.
• W2954234894 hasConcept C126322002 @default.
• W2954234894 hasConcept C126894567 @default.
• W2954234894 hasConcept C134018914 @default.
• W2954234894 hasConcept C142724271 @default.
• W2954234894 hasConcept C159641895 @default.
• W2954234894 hasConcept C204787440 @default.
• W2954234894 hasConcept C27081682 @default.
• W2954234894 hasConcept C2778653478 @default.
• W2954234894 hasConcept C2780306776 @default.
• W2954234894 hasConcept C2781203188 @default.
• W2954234894 hasConcept C555293320 @default.
• W2954234894 hasConcept C71924100 @default.
• W2954234894 hasConcept C77411442 @default.
• W2954234894 hasConcept C90924648 @default.
• W2954234894 hasConceptScore W2954234894C126322002 @default.
• W2954234894 hasConceptScore W2954234894C126894567 @default.
• W2954234894 hasConceptScore W2954234894C134018914 @default.
• W2954234894 hasConceptScore W2954234894C142724271 @default.
• W2954234894 hasConceptScore W2954234894C159641895 @default.
• W2954234894 hasConceptScore W2954234894C204787440 @default.
• W2954234894 hasConceptScore W2954234894C27081682 @default.
• W2954234894 hasConceptScore W2954234894C2778653478 @default.
• W2954234894 hasConceptScore W2954234894C2780306776 @default.
• W2954234894 hasConceptScore W2954234894C2781203188 @default.
• W2954234894 hasConceptScore W2954234894C555293320 @default.
• W2954234894 hasConceptScore W2954234894C71924100 @default.
• W2954234894 hasConceptScore W2954234894C77411442 @default.
• W2954234894 hasConceptScore W2954234894C90924648 @default.
• W2954234894 hasFunder F4320321625 @default.
• W2954234894 hasIssue "8" @default.
• W2954234894 hasLocation W29542348941 @default.
• W2954234894 hasLocation W29542348942 @default.
• W2954234894 hasLocation W29542348943 @default.
• W2954234894 hasOpenAccess W2954234894 @default.
• W2954234894 hasPrimaryLocation W29542348941 @default.
• W2954234894 hasRelatedWork W2006242568 @default.
• W2954234894 hasRelatedWork W2124543160 @default.
• W2954234894 hasRelatedWork W2140445493 @default.
• W2954234894 hasRelatedWork W3011378569 @default.
• W2954234894 hasRelatedWork W3037492966 @default.

• next